Founded in 2002, the Bristol-Myers Squibb Foundation's Delivering Hope initiative aims to reduce the incidence and spread of hepatitis B and C across continental Asia. The program's initial focus centered on preventing mother-to-child transmission of hepatitis B and promoting hepatitis B vaccination in China. After some initial success with that initiative, Delivering Hope has been able to broaden its focus to other parts of Asia. Currently, it has active programs running in Taiwan, India, Japan, and China.
After a slow start, Delivering Hope has gone from funding one or two projects per year to eight or more, often spreading its influence across a wide geographic range. Throughout its growth, the program has always sought to fund the community-based initiatives that work directly with needy populations. Bristol-Myers isn't about abstract lab breakthroughs that may take years to trickle down to humanity in general. With Delivering Hope, the foundation wants to put its money directly in the hands of the clinics, hospitals, and foundations that need it.
Recently, Delivering Hope's award sums ranged from $99,923 to $414,995 for a one-year grant. Its 2010 partnerships (grantees) ranged from public health, to education and outreach, to research: $246,932 for a Chinese study that will enhance understanding of the socioeconomic issues facing hepatitis C patients; $246,053 to build hepatitis B education into Taiwanese schools, raising awareness among students; and $248,664 to provide at-birth hepatitis B vaccinations to newborns in the interest of preventing mother-to-child transmission of the virus.
As the foundation has gained experience making these kinds of awards, it has been able to increase both award size and frequency, although it hasn't strayed from Delivering Hope's initial focus on community partnerships and direct-line giving. Keep that in mind when pursuing funding from this giant, whether underneath its Hepatitis in Asia program or in other fields.